Knowledge (XXG)

Oxelumab

Source 📝

1509: 1452: 22: 1601: 402: 166: 306: 1557: 1493: 1581: 395: 32: 129: 1576: 1550: 1486: 388: 1586: 1411: 1596: 357: 1543: 1479: 1383: 47: 1393: 364: 223: 90: 1591: 1428: 62: 977: 69: 1416: 76: 489: 411: 693: 58: 1523: 1459: 187: 139: 122: 878: 837: 677: 469: 769: 439: 380: 338: 1527: 1463: 196: 759: 749: 248: 232: 1520: 1177: 953: 368: 1516: 1422: 83: 1570: 1332: 1133: 1078: 1003: 963: 883: 777: 423: 415: 1322: 1307: 1287: 1277: 1256: 1172: 1113: 1098: 1068: 1048: 1043: 1018: 998: 993: 988: 938: 928: 918: 868: 863: 858: 787: 672: 656: 559: 549: 544: 519: 459: 1388: 1378: 1317: 1302: 1292: 1282: 1261: 1246: 1231: 1226: 1221: 1196: 1149: 1128: 1123: 1118: 1108: 1103: 1088: 1063: 1053: 1033: 1013: 1008: 973: 968: 958: 948: 943: 913: 903: 873: 827: 822: 812: 797: 782: 754: 739: 724: 719: 714: 682: 625: 620: 610: 590: 569: 564: 534: 454: 21: 1508: 1451: 1348: 1327: 1312: 1297: 1241: 1236: 1216: 1211: 1182: 1156: 1093: 1073: 1058: 1038: 1028: 983: 933: 923: 898: 893: 888: 853: 848: 817: 802: 744: 734: 729: 709: 646: 641: 630: 600: 595: 539: 514: 499: 484: 479: 449: 287: 207: 1251: 1083: 908: 807: 792: 651: 615: 605: 579: 574: 554: 529: 524: 509: 504: 474: 444: 334: 358:"Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab" 661: 494: 464: 115: 1138: 1023: 151: 1363: 327: 144: 384: 15: 326:
is a human monoclonal antibody designed for the treatment of
39: 1531: 1467: 313: 43: 1371: 1361: 1341: 1270: 1204: 1195: 1164: 836: 768: 702: 431: 422: 286: 247: 242: 222: 206: 186: 181: 165: 160: 150: 138: 128: 121: 195: 1602:Antineoplastic and immunomodulating drug stubs 1551: 1487: 396: 8: 114: 48:introducing citations to additional sources 1558: 1544: 1494: 1480: 1368: 1201: 428: 403: 389: 381: 231: 38:Relevant discussion may be found on the 349: 113: 7: 1582:Drugs developed by Hoffmann-La Roche 1505: 1503: 1448: 1446: 1530:. You can help Knowledge (XXG) by 1466:. You can help Knowledge (XXG) by 14: 1507: 1450: 265: 259: 31:relies largely or entirely on a 20: 1577:Drugs not assigned an ATC code 277: 271: 253: 1: 1587:Drugs developed by Genentech 365:American Medical Association 1618: 1502: 1445: 333:Oxelumab was developed by 243:Chemical and physical data 1597:Monoclonal antibody stubs 1406: 303: 1462:–related article is a 490:Camidanlumab tesirine 412:Monoclonal antibodies 1165:Chimeric + humanized 694:Nivolumab/relatlimab 337:and co-developed by 44:improve this article 1460:monoclonal antibody 123:Monoclonal antibody 118: 111:Monoclonal antibody 1592:Experimental drugs 1433:Never to phase III 879:Certolizumab pegol 846:Immunosuppressive: 1539: 1538: 1475: 1474: 1443: 1442: 1402: 1401: 1357: 1356: 1191: 1190: 1146:Immune activation 638:Immune activation 440:Immunosuppression 321: 320: 109: 108: 94: 1609: 1560: 1553: 1546: 1521:immunomodulatory 1511: 1504: 1496: 1489: 1482: 1454: 1447: 1369: 1202: 760:Zolimomab aritox 750:Telimomab aritox 429: 405: 398: 391: 382: 376: 375: 373: 367:. Archived from 362: 354: 317: 316: 309: 298: 296: 279: 273: 267: 261: 255: 235: 199: 119: 117: 104: 101: 95: 93: 52: 24: 16: 1617: 1616: 1612: 1611: 1610: 1608: 1607: 1606: 1567: 1566: 1565: 1564: 1501: 1500: 1444: 1439: 1438: 1423:Clinical trials 1398: 1353: 1337: 1266: 1187: 1178:Rozanolixizumab 1166: 1160: 1152: 1141: 954:Lulizumab pegol 832: 764: 698: 418: 409: 379: 374:on 12 May 2013. 371: 360: 356: 355: 351: 347: 312: 310: 307:(what is this?) 304: 294: 292: 282: 276: 270: 264: 258: 238: 218: 202: 177: 112: 105: 99: 96: 53: 51: 37: 25: 12: 11: 5: 1615: 1613: 1605: 1604: 1599: 1594: 1589: 1584: 1579: 1569: 1568: 1563: 1562: 1555: 1548: 1540: 1537: 1536: 1517:antineoplastic 1512: 1499: 1498: 1491: 1484: 1476: 1473: 1472: 1455: 1441: 1440: 1437: 1436: 1435: 1434: 1431: 1420: 1414: 1408: 1407: 1404: 1403: 1400: 1399: 1397: 1396: 1391: 1386: 1381: 1375: 1373: 1366: 1359: 1358: 1355: 1354: 1352: 1351: 1345: 1343: 1339: 1338: 1336: 1335: 1330: 1325: 1320: 1315: 1310: 1305: 1300: 1295: 1290: 1285: 1280: 1274: 1272: 1268: 1267: 1265: 1264: 1259: 1254: 1249: 1244: 1239: 1234: 1229: 1224: 1219: 1214: 1208: 1206: 1199: 1193: 1192: 1189: 1188: 1186: 1185: 1180: 1175: 1169: 1167: 1162: 1161: 1143: 1142: 1136: 1131: 1126: 1121: 1116: 1111: 1106: 1101: 1096: 1091: 1086: 1081: 1076: 1071: 1066: 1061: 1056: 1051: 1046: 1041: 1036: 1031: 1026: 1021: 1016: 1011: 1006: 1001: 996: 991: 986: 981: 978:+hyaluronidase 971: 966: 961: 956: 951: 946: 941: 936: 931: 926: 921: 916: 911: 906: 901: 896: 891: 886: 881: 876: 871: 866: 861: 856: 851: 842: 840: 834: 833: 831: 830: 825: 820: 815: 810: 805: 800: 795: 790: 785: 780: 774: 772: 766: 765: 763: 762: 757: 752: 747: 742: 737: 732: 727: 722: 717: 712: 706: 704: 700: 699: 697: 696: 686: 685: 680: 675: 665: 664: 659: 654: 649: 644: 634: 633: 628: 623: 618: 613: 608: 603: 598: 593: 588: 582: 577: 572: 567: 562: 557: 552: 547: 542: 537: 532: 527: 522: 517: 512: 507: 502: 497: 492: 487: 482: 477: 472: 467: 462: 457: 452: 447: 435: 433: 426: 420: 419: 410: 408: 407: 400: 393: 385: 378: 377: 348: 346: 343: 319: 318: 301: 300: 290: 284: 283: 280: 274: 268: 262: 256: 251: 245: 244: 240: 239: 237: 236: 228: 226: 220: 219: 217: 216: 212: 210: 204: 203: 201: 200: 192: 190: 184: 183: 179: 178: 176: 175: 171: 169: 163: 162: 158: 157: 154: 148: 147: 142: 136: 135: 134:Whole antibody 132: 126: 125: 110: 107: 106: 42:. Please help 28: 26: 19: 13: 10: 9: 6: 4: 3: 2: 1614: 1603: 1600: 1598: 1595: 1593: 1590: 1588: 1585: 1583: 1580: 1578: 1575: 1574: 1572: 1561: 1556: 1554: 1549: 1547: 1542: 1541: 1535: 1533: 1529: 1526:article is a 1525: 1522: 1518: 1513: 1510: 1506: 1497: 1492: 1490: 1485: 1483: 1478: 1477: 1471: 1469: 1465: 1461: 1456: 1453: 1449: 1432: 1430: 1427: 1426: 1424: 1421: 1418: 1415: 1413: 1410: 1409: 1405: 1395: 1392: 1390: 1387: 1385: 1382: 1380: 1377: 1376: 1374: 1370: 1367: 1365: 1362:Inflammatory 1360: 1350: 1347: 1346: 1344: 1340: 1334: 1333:Tildrakizumab 1331: 1329: 1326: 1324: 1321: 1319: 1316: 1314: 1311: 1309: 1306: 1304: 1301: 1299: 1296: 1294: 1291: 1289: 1286: 1284: 1281: 1279: 1276: 1275: 1273: 1269: 1263: 1260: 1258: 1255: 1253: 1250: 1248: 1245: 1243: 1240: 1238: 1235: 1233: 1230: 1228: 1225: 1223: 1220: 1218: 1215: 1213: 1210: 1209: 1207: 1203: 1200: 1198: 1194: 1184: 1181: 1179: 1176: 1174: 1171: 1170: 1168: 1163: 1159: 1158: 1155: 1151: 1147: 1140: 1137: 1135: 1134:Vobarilizumab 1132: 1130: 1127: 1125: 1122: 1120: 1117: 1115: 1112: 1110: 1107: 1105: 1102: 1100: 1097: 1095: 1092: 1090: 1087: 1085: 1082: 1080: 1079:Spartalizumab 1077: 1075: 1072: 1070: 1067: 1065: 1062: 1060: 1057: 1055: 1052: 1050: 1047: 1045: 1042: 1040: 1037: 1035: 1032: 1030: 1027: 1025: 1022: 1020: 1017: 1015: 1012: 1010: 1007: 1005: 1004:Pembrolizumab 1002: 1000: 997: 995: 992: 990: 987: 985: 982: 979: 975: 972: 970: 967: 965: 964:Mogamulizumab 962: 960: 957: 955: 952: 950: 947: 945: 942: 940: 937: 935: 932: 930: 927: 925: 922: 920: 917: 915: 912: 910: 907: 905: 902: 900: 897: 895: 892: 890: 887: 885: 884:Crizanlizumab 882: 880: 877: 875: 872: 870: 867: 865: 862: 860: 857: 855: 852: 850: 847: 844: 843: 841: 839: 835: 829: 826: 824: 821: 819: 816: 814: 811: 809: 806: 804: 801: 799: 796: 794: 791: 789: 786: 784: 781: 779: 778:Andecaliximab 776: 775: 773: 771: 767: 761: 758: 756: 753: 751: 748: 746: 743: 741: 738: 736: 733: 731: 728: 726: 723: 721: 718: 716: 713: 711: 708: 707: 705: 701: 695: 691: 688: 687: 684: 681: 679: 676: 674: 670: 667: 666: 663: 660: 658: 655: 653: 650: 648: 645: 643: 639: 636: 635: 632: 629: 627: 624: 622: 619: 617: 614: 612: 609: 607: 604: 602: 599: 597: 594: 592: 589: 586: 583: 581: 578: 576: 573: 571: 568: 566: 563: 561: 558: 556: 553: 551: 548: 546: 543: 541: 538: 536: 533: 531: 528: 526: 523: 521: 518: 516: 513: 511: 508: 506: 503: 501: 498: 496: 493: 491: 488: 486: 483: 481: 478: 476: 473: 471: 468: 466: 463: 461: 458: 456: 453: 451: 448: 446: 442: 441: 437: 436: 434: 430: 427: 425: 424:Immune system 421: 417: 416:immune system 413: 406: 401: 399: 394: 392: 387: 386: 383: 370: 366: 359: 353: 350: 344: 342: 340: 336: 331: 329: 325: 315: 308: 302: 291: 289: 285: 252: 250: 246: 241: 234: 230: 229: 227: 225: 221: 214: 213: 211: 209: 205: 198: 194: 193: 191: 189: 185: 180: 173: 172: 170: 168: 164: 161:Clinical data 159: 155: 153: 149: 146: 143: 141: 137: 133: 131: 127: 124: 120: 103: 92: 89: 85: 82: 78: 75: 71: 68: 64: 61: –  60: 56: 55:Find sources: 49: 45: 41: 35: 34: 33:single source 29:This article 27: 23: 18: 17: 1532:expanding it 1514: 1468:expanding it 1457: 1323:Risankizumab 1308:Lebrikizumab 1288:Clazakizumab 1278:Anrukinzumab 1257:Tralokinumab 1173:Otelixizumab 1153: 1145: 1144: 1114:Tregalizumab 1099:Tislelizumab 1069:Satralizumab 1049:Rontalizumab 1044:Retifanlimab 1019:Plozalizumab 999:Pateclizumab 994:Pascolizumab 989:Ozoralizumab 939:Lampalizumab 929:Inebilizumab 919:Fontolizumab 869:Camrelizumab 864:Benralizumab 859:Atezolizumab 845: 788:Clenoliximab 689: 673:Bertilimumab 668: 657:Tremelimumab 637: 584: 560:Mavrilimumab 550:Lirentelimab 545:Lerdelimumab 520:Fresolimumab 460:Atorolimumab 438: 369:the original 352: 332: 323: 322: 311:   305:   197:1186098-83-8 156:OX-40 ligand 100:January 2024 97: 87: 80: 73: 66: 54: 30: 1419:from market 1389:Lemalesomab 1384:Fanolesomab 1379:Besilesomab 1318:Perakizumab 1303:Mirikizumab 1293:Gevokizumab 1283:Bimekizumab 1262:Ustekinumab 1247:Secukinumab 1232:Fezakinumab 1227:Canakinumab 1222:Briakinumab 1197:Interleukin 1150:Dostarlimab 1129:Visilizumab 1124:Vedolizumab 1119:Vatelizumab 1109:Toralizumab 1104:Tocilizumab 1089:Teclistamab 1064:Samalizumab 1054:Rovelizumab 1034:Ravulizumab 1014:Pidilizumab 1009:Pexelizumab 974:Ocrelizumab 969:Natalizumab 959:Mepolizumab 949:Ligelizumab 944:Letolizumab 914:Etrolizumab 904:Epratuzumab 874:Cedelizumab 828:Vapaliximab 823:Teneliximab 813:Lumiliximab 798:Gomiliximab 783:Basiliximab 755:Vepalimomab 740:Nerelimomab 725:Gavilimomab 720:Faralimomab 715:Elsilimomab 690:Combination 683:Zanolimumab 678:Ontamalimab 626:Ulocuplumab 621:Tezepelumab 611:Sifalimumab 591:Pamrevlumab 570:Morolimumab 565:Metelimumab 535:Lanadelumab 470:Avdoralimab 455:Anifrolumab 299: g·mol 182:Identifiers 1571:Categories 1349:Lokivetmab 1342:Veterinary 1328:Spesolimab 1313:Olokizumab 1298:Ixekizumab 1242:Guselkumab 1237:Fletikumab 1217:Brazikumab 1212:Bermekimab 1183:Sutimlimab 1157:Ibalizumab 1094:Teplizumab 1074:Siplizumab 1059:Ruplizumab 1039:Reslizumab 1029:Quilizumab 984:Omalizumab 934:Itolizumab 924:Frexalimab 899:Efalizumab 894:Eculizumab 889:Daclizumab 854:Aselizumab 849:Apolizumab 818:Priliximab 803:Infliximab 745:Odulimomab 735:Maslimomab 730:Inolimomab 710:Afelimomab 647:Durvalumab 642:Ipilimumab 631:Varlilumab 601:Relatlimab 596:Placulumab 540:Lenzilumab 515:Emapalumab 500:Cemiplimab 485:Brodalumab 480:Bleselumab 450:Adalimumab 345:References 288:Molar mass 233:67GFR7JCMN 208:ChemSpider 188:CAS Number 70:newspapers 59:"Oxelumab" 1429:Phase III 1417:Withdrawn 1394:Sulesomab 1271:Humanized 1252:Sirukumab 1084:Talizumab 909:Erlizumab 838:Humanized 808:Keliximab 793:Galiximab 652:Nivolumab 616:Tabalumab 606:Sarilumab 580:Oleclumab 575:Namilumab 555:Lirilumab 530:Ianalumab 525:Golimumab 510:Eldelumab 505:Dupilumab 475:Belimumab 445:Abrilumab 335:Genentech 40:talk page 770:Chimeric 662:Urelumab 585:Oxelumab 495:Carlumab 465:Avelumab 414:for the 324:Oxelumab 314:(verify) 167:ATC code 116:Oxelumab 1364:lesions 1139:TGN1412 1024:PRO 140 249:Formula 84:scholar 1412:WHO-EM 1154:Other: 328:asthma 152:Target 140:Source 86:  79:  72:  65:  57:  1515:This 1458:This 1372:Mouse 1205:Human 703:Mouse 669:Other 432:Human 372:(PDF) 361:(PDF) 339:Roche 145:Human 91:JSTOR 77:books 1528:stub 1524:drug 1464:stub 275:2014 269:1704 263:9920 257:6424 224:UNII 215:none 174:none 130:Type 63:news 1519:or 297:.46 295:594 293:144 46:by 1573:: 1425:: 1148:: 692:: 671:: 640:: 443:: 363:. 341:. 330:. 281:42 1559:e 1552:t 1545:v 1534:. 1495:e 1488:t 1481:v 1470:. 980:) 976:( 587:§ 404:e 397:t 390:v 278:S 272:O 266:N 260:H 254:C 102:) 98:( 88:· 81:· 74:· 67:· 50:. 36:.

Index


single source
talk page
improve this article
introducing citations to additional sources
"Oxelumab"
news
newspapers
books
scholar
JSTOR
Monoclonal antibody
Type
Source
Human
Target
ATC code
CAS Number
1186098-83-8
ChemSpider
UNII
67GFR7JCMN
Formula
Molar mass
(what is this?)
(verify)
asthma
Genentech
Roche
"Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab"

Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.